269 related articles for article (PubMed ID: 34128342)
41. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
42.
Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G
Front Immunol; 2024; 15():1364329. PubMed ID: 38698844
[TBL] [Abstract][Full Text] [Related]
43. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
44. Comprehensive data analysis of genomics, epigenomics, and transcriptomics to identify specific biomolecular markers for prostate adenocarcinoma.
Ye C; Wang H; Li Z; Xia C; Yuan S; Yan R; Yang X; Ma T; Wen X; Yang D
Transl Androl Urol; 2021 Jul; 10(7):3030-3045. PubMed ID: 34430406
[TBL] [Abstract][Full Text] [Related]
45. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
46. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
47. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
48. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract][Full Text] [Related]
49. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
[TBL] [Abstract][Full Text] [Related]
50. Copy number alterations are associated with metastatic-lethal progression in prostate cancer.
Wang X; Grasso CS; Jordahl KM; Kolb S; Nyame YA; Wright JL; Ostrander EA; Troyer DA; Lance R; Feng Z; Dai JY; Stanford JL
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):494-506. PubMed ID: 32071439
[TBL] [Abstract][Full Text] [Related]
51. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
52. tRNA-Derived RNA Fragments Are Novel Biomarkers for Diagnosis, Prognosis, and Tumor Subtypes in Prostate Cancer.
Liu W; Yu M; Cheng S; Zhou X; Li J; Lu Y; Liu P; Ding S
Curr Oncol; 2023 Jan; 30(1):981-999. PubMed ID: 36661724
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
54. Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data.
Huang H; Xu H; Li P; Ye X; Chen W; Chen W; Huang X
Bioengineered; 2021 Dec; 12(1):5504-5515. PubMed ID: 34514952
[TBL] [Abstract][Full Text] [Related]
55. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
[TBL] [Abstract][Full Text] [Related]
56. Identification of Molecular Subtype and Prognostic Signature for Prostate Adenocarcinoma based on Neutrophil Extracellular Traps.
Zheng Y; Sun H; Yang S; Liu W; Jiang G
J Cancer; 2024; 15(9):2678-2690. PubMed ID: 38577608
[No Abstract] [Full Text] [Related]
57. The cGAS-STING pathway-related gene signature can predict patient prognosis and immunotherapy responses in prostate adenocarcinoma.
Zhuo X; Dai H; Yu S
Medicine (Baltimore); 2022 Dec; 101(50):e31290. PubMed ID: 36550819
[TBL] [Abstract][Full Text] [Related]
58. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
59. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
60. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
